Literature DB >> 28713680

Targeting the epigenome in malignant pleural mesothelioma.

Kaitlin C McLoughlin1, Andrew S Kaufman1, David S Schrump1.   

Abstract

Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.

Entities:  

Keywords:  DNA demethylating agents; EZH2 inhibitor; Malignant pleural mesotheliomas (MPM); epigenetics, DNA methylation; immune checkpoint inhibitor; polycomb

Year:  2017        PMID： 28713680      PMCID： PMC5504118          DOI： 10.21037/tlcr.2017.06.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  136 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

Review 2.  Targeting epigenetic mediators of gene expression in thoracic malignancies.

Authors:  David S Schrump
Journal:  Biochim Biophys Acta       Date:  2012-04-09

Review 3.  lncRNAs: linking RNA to chromatin.

Authors:  John L Rinn
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-08-01       Impact factor: 10.005

Review 4.  The role of Sp1 and Sp3 in normal and cancer cell biology.

Authors:  Lin Li; James R Davie
Journal:  Ann Anat       Date:  2010-08-06       Impact factor: 2.698

5.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

6.  Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.

Authors:  Shifeng Su; John T Minges; Gail Grossman; Amanda J Blackwelder; James L Mohler; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2013-07-12       Impact factor: 5.157

Review 7.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

8.  Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.

Authors:  Jiri Neuzil; Emma Swettenham; Nina Gellert
Journal:  Biochem Biophys Res Commun       Date:  2004-01-30       Impact factor: 3.575

9.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

10.  An Integrated Analysis of the Genome-Wide Profiles of DNA Methylation and mRNA Expression Defining the Side Population of a Human Malignant Mesothelioma Cell Line.

Authors:  Myung-Chul Kim; Na-Yon Kim; Yu-Ri Seo; Yongbaek Kim
Journal:  J Cancer       Date:  2016-07-26       Impact factor: 4.207
View more
  13 in total

1.  Genomic landscape of pleural and peritoneal mesothelioma tumours.

Authors:  Stefanie Hiltbrunner; Zoe Fleischmann; Ethan S Sokol; Martin Zoche; Emanuela Felley-Bosco; Alessandra Curioni-Fontecedro
Journal:  Br J Cancer       Date:  2022-09-22       Impact factor: 9.075

2.  Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.

Authors:  Silvia Mola; Giulia Pinton; Marco Erreni; Marco Corazzari; Marco De Andrea; Ambra A Grolla; Veronica Martini; Laura Moro; Chiara Porta
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 3.  Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Cancers (Basel)       Date:  2018-03-22       Impact factor: 6.639

Review 4.  Genomics and Epigenetics of Malignant Mesothelioma.

Authors:  Adam P Sage; Victor D Martinez; Brenda C Minatel; Michelle E Pewarchuk; Erin A Marshall; Gavin M MacAulay; Roland Hubaux; Dustin D Pearson; Aaron A Goodarzi; Graham Dellaire; Wan L Lam
Journal:  High Throughput       Date:  2018-07-27

5.  5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin.

Authors:  Matteo Bosio; Elena Salvaterra; Francesca Datturi; Patrizia Morbini; Michele Zorzetto; Simona Inghilleri; Stefano Tomaselli; Patrizia Mangiarotti; Federica Meloni; Isa Cerveri; Giulia Maria Stella
Journal:  Multidiscip Respir Med       Date:  2018-08-02

6.  Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.

Authors:  Yuna Blum; Clément Meiller; Lisa Quetel; Nabila Elarouci; Mira Ayadi; Danisa Tashtanbaeva; Lucile Armenoult; François Montagne; Robin Tranchant; Annie Renier; Leanne de Koning; Marie-Christine Copin; Paul Hofman; Véronique Hofman; Henri Porte; Françoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Aurélien de Reyniès; Didier Jean
Journal:  Nat Commun       Date:  2019-03-22       Impact factor: 14.919

7.  UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.

Authors:  Emily S Reardon; Vivek Shukla; Sichuan Xi; Sudheer K Gara; Yi Liu; David Straughan; Mary Zhang; Julie A Hong; Eden C Payabyab; Anju Kumari; William G Richards; Assunta De Rienzo; Raffit Hassan; Markku Miettinen; Liqiang Xi; Mark Raffeld; Lisa T Uechi; Xinmin Li; Ruihong Wang; Haobin Chen; Chuong D Hoang; Raphael Bueno; David S Schrump
Journal:  J Thorac Oncol       Date:  2020-09-11       Impact factor: 15.609

Review 8.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

Review 9.  The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models.

Authors:  Christophe Blanquart; Marie-Claude Jaurand; Didier Jean
Journal:  Front Oncol       Date:  2020-03-25       Impact factor: 6.244

Review 10.  Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.

Authors:  David Michael Abbott; Chandra Bortolotto; Silvia Benvenuti; Andrea Lancia; Andrea Riccardo Filippi; Giulia Maria Stella
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.